Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Drugs of today"
DOI: 10.1358/dot.2023.59.1.3476574
Abstract: On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who… read more here.
Keywords: 177 vipivotide; prostate; lutetium 177; vipivotide tetraxetan ... See more keywords